プロフィール詳細

プロジェクトを作成

★★★★★

☆☆☆☆☆

★★★★★

☆☆☆☆☆

Prashant P.に依頼

India

Oncology Scientist, Expert in Drug Discovery & Scientific Communication

プロフィール概要

I am an oncology scientist with 13+ years of experience in drug discovery, specializing in in vivo pharmacology and translational research, complemented by expertise in in vitro assays and ex vivo studies. My work has involved designing and leading efficacy studies, developing study protocols, and collaborating with cross-functional teams to advance oncology pipelines. Currently, I am expanding into medical writing and scientific communication, applying my combined in vivo, in vitro, and ex vivo expertise to deliver clear, accurate study reports, scientific summaries, and client-ready proposals that connect complex data with actionable insights.

専門分野

• ☆ Drug Discovery
• ☆ Drug Development
• ☆ Small Molecule Drug Development
• ☆ Biologic & Biosimilar Development
• ☆ Preclinical Research
• ☆ Preclinical Pharmacology
• ☆ Drug Efficacy Testing
• ☆ Oncology

サービス

• Writing
• Research
• Consulting
• Data & AI

Writing Medical Writing, Technical Writing

Research Meta-Research, Technology Scouting, Fact Checking, Gap Analysis, Scientific and Technical Research, Systematic Literature Review, Secondary Data Collection

Consulting Healthcare Consulting, Scientific and Technical Consulting

Data & AI Image Analysis, Data Visualization

職務経験

Staff Scientist I

Labcorp Early Development Laboratories

12月 2022 - 現在

Senior Research Scientist

Biofusion Therapeutics Ltd.|

7月 2021 - 11月 2022

Principal Scientist

Biocon Ltd

8月 2015 - 6月 2021

Executive - Pharmacology

NATCO Pharma

2月 2015 - 7月 2015

Research Fellow

ACTREC, Tata Memorial Centre

9月 2014 - 1月 2015

Research Associate

Piramal Life Sciences Ltd.

5月 2012 - 8月 2014

学歴

M.Sc (Master of Science)

Manipal Academy of Higher Education (MAHE)

9月 2009 - 7月 2011

B.Sc. Biology

Deen Dayal Upadhyay Gorakhpur University - India

8月 2006 - 6月 2009

認定資格

• 認定資格の詳細は未入力です。

出版物

JOURNAL ARTICLE

Milind Sagar, Prashant Kumar Pandey, Shiva Sharma, Manisha Rastogi (2026). Antitumor Activity of Elaeocarpus ganitrus (Rudraksha) Bead Extract Mediated Silver Nanoparticles in Preclinical Models . BioNanoScience.

Srinivas Reddy Boreddy, Reshmi Nair, Prashant Kumar Pandey, Anshu Kuriakose, Shivakumar Bhadravathi Marigowda, Chaitali Dey, Arindam Banerjee, Hanumant Kulkarni, Milind Sagar, Shiv Ram Krishn, et al. (2023). BCA101 Is a Tumor-Targeted Bifunctional Fusion Antibody That Simultaneously Inhibits EGFR and TGFβ Signaling to Durably Suppress Tumor Growth . Cancer Research.

Abstract 6339: BCA101, a novel tumor-targeted bifunctional fusion antibody simultaneously inhibiting EGFR and TGF-β signaling with potential for durable tumor growth inhibition @article{Boreddy_2023, title={Abstract 6339: BCA101, a novel tumor-targeted bifunctional fusion antibody simultaneously inhibiting EGFR and TGF-β signaling with potential for durable tumor growth inhibition}, volume={83}, ISSN={1538-7445}, url={http://dx.doi.org/10.1158/1538-7445.am2023-6339}, DOI={10.1158/1538-7445.am2023-6339}, number={7_Supplement}, journal={Cancer Research}, publisher={American Association for Cancer Research (AACR)}, author={Boreddy, Srinivas Reddy and Nair, Reshmi and Pandey, Prashant Kumar and Kuriakose, Anshu and Banerjee, Arindam and Dey, Chaitali and R, Madhukara A and Shivakumar, Bhadravathi Marigowda and Kulkarni, Hanumant and Sagar, Milind and V, Prashantha Kumar M. and Krishn, Shiv Ram and Bhatnagar, Jaya and Kuriakose, Moni Abhram and Reddy, Ram Bhupal and Suresh, Amritha and Moole, Praveen Reddy and Bughani, Usha and Tan, Seng-Lai and Nair, Pradip and Salazar, Rachel}, year={2023}, month=apr, pages={6339–6339} } . Cancer Research.

874 Development of BCA101, a bifunctional antibody capable of simultaneously disabling EGFR and TGFβ signaling, as novel single-agent immunotherapy @article{Boreddy_2021, title={874 Development of BCA101, a bifunctional antibody capable of simultaneously disabling EGFR and TGFβ signaling, as novel single-agent immunotherapy}, volume={9}, ISSN={2051-1426}, url={http://dx.doi.org/10.1136/jitc-2021-sitc2021.874}, DOI={10.1136/jitc-2021-sitc2021.874}, number={Suppl 2}, journal={Journal for ImmunoTherapy of Cancer}, publisher={BMJ}, author={Boreddy, Srinivas Reddy and Nair, Reshmi and Banerjee, Arindam and Kuriakose, Anshu and Pandey, Prashant Kumar and Dey, Chaitali and Shri, Meena and Rao, Shruthi and Shivakumar, Bhadravathi Marigowda and Kuriakose, Moni Abhram and Reddy, Ram Bhupal and Suresh, Amritha and Moole, Praveen Reddy and Bughani, Usha and Tan, Seng-Lai and Nair, Pradip}, year={2021}, month=nov, pages={A915–A916} } . Journal for ImmunoTherapy of Cancer.

P7170, a novel inhibitor of mTORC1/mTORC2 and Activin receptor-like Kinase 1 (ALK1) inhibits the growth of non small cell lung cancer @article{Venkatesha_2014, title={P7170, a novel inhibitor of mTORC1/mTORC2 and Activin receptor-like Kinase 1 (ALK1) inhibits the growth of non small cell lung cancer}, volume={13}, ISSN={1476-4598}, url={http://dx.doi.org/10.1186/1476-4598-13-259}, DOI={10.1186/1476-4598-13-259}, number={1}, journal={Molecular Cancer}, publisher={Springer Science and Business Media LLC}, author={Venkatesha, Venkatasubbaiah A and Joshi, Asavari and Venkataraman, Magesh and Sonawane, Vinay and Bhatia, Dimple and Tannu, Prashant and Bose, Julie and Choudhari, Sarika and Srivastava, Ankita and Pandey, Prashant Kumar and Lad, Vaibhavi J and Sangana, Ramachandra and Ahmed, Tausif and Damre, Anagha and Deore, Vijaykumar and Sahu, Bichismita and Kumar, Sanjay and Sharma, Somesh and Agarwal, Veena R}, year={2014}, month=dec } . Molecular Cancer.

Abstract 4521: P7170, a novel inhibitor of phosphoinositide 3-kinase (PI3K)-mammalian target of rapamycin (mTOR) and activin receptor-like kinase 1 (ALK1) shows anti-tumor activity in triple negative breast cancer @article{Agarwal_2014, title={Abstract 4521: P7170, a novel inhibitor of phosphoinositide 3-kinase (PI3K)-mammalian target of rapamycin (mTOR) and activin receptor-like kinase 1 (ALK1) shows anti-tumor activity in triple negative breast cancer}, volume={74}, ISSN={1538-7445}, url={http://dx.doi.org/10.1158/1538-7445.am2014-4521}, DOI={10.1158/1538-7445.am2014-4521}, number={19_Supplement}, journal={Cancer Research}, publisher={American Association for Cancer Research (AACR)}, author={Agarwal, Veena R. and Bhatia, Dimple and Joshi, Asavari and Mishra, Prabha and Bharadwaj, Kalyani G. and lobo, Aurelio S. and Menon, Pranoy and Dhar, Payal and Pandey, Prashant and Srinivasa, Sreesha and sonawane, vinay}, year={2014}, month=oct, pages={4521–4521} } . Cancer Research.

Abstract 3437: P276, a cyclin-dependent kinase inhibitor with antitumor activity against high-risk human cervical cancer. @article{Shangary_2013, title={Abstract 3437: P276, a cyclin-dependent kinase inhibitor with antitumor activity against high-risk human cervical cancer.}, volume={73}, ISSN={1538-7445}, url={http://dx.doi.org/10.1158/1538-7445.am2013-3437}, DOI={10.1158/1538-7445.am2013-3437}, number={8_Supplement}, journal={Cancer Research}, publisher={American Association for Cancer Research (AACR)}, author={Shangary, Sanjeev Kumar and Deshpande, Gandhali and Sonawane, Vinay and Venkatasubbaiah, Venkatesha and Jalota-Badhwar, Archana and Joshi, Asavari and Mayekar, Manoj and Shirsath, Nitesh and Pandey, Prashant and Agarwal, Veena R.}, year={2013}, month=apr, pages={3437–3437} } . Cancer Research.

PREPRINT

Srinivas Reddy Boreddy, Reshmi Nair, Prashant Kumar Pandey, Anshu Kuriakose, Shivakumar Bhadravathi Marigowda, Chaitali Dey, Arindam Banerjee, Hanumant Kulkarni, Milind Sagar, Shiv Ram Krishn, et al. (2025). Supplementary Data from BCA101 Is a Tumor-Targeted Bifunctional Fusion Antibody That Simultaneously Inhibits EGFR and TGFβ Signaling to Durably Suppress Tumor Growth .

Srinivas Reddy Boreddy, Reshmi Nair, Prashant Kumar. Pandey, Anshu Kuriakose, Shivakumar Bhadravathi. Marigowda, Chaitali Dey, Arindam Banerjee, Hanumant Kulkarni, Milind Sagar, Shiv Ram Krishn, et al. (2024). Data from BCA101 is a Tumor-Targeted Bifunctional Fusion Antibody that Simultaneously Inhibits EGFR and TGF-β Signalling to Durably Suppress Tumor Growth .

Srinivas Reddy Boreddy, Reshmi Nair, Prashant Kumar. Pandey, Anshu Kuriakose, Shivakumar Bhadravathi. Marigowda, Chaitali Dey, Arindam Banerjee, Hanumant Kulkarni, Milind Sagar, Shiv Ram Krishn, et al. (2024). Supplementary Data from BCA101 is a Tumor-Targeted Bifunctional Fusion Antibody that Simultaneously Inhibits EGFR and TGF-β Signalling to Durably Suppress Tumor Growth .

Srinivas Reddy Boreddy, Reshmi Nair, Prashant Kumar. Pandey, Anshu Kuriakose, Shivakumar Bhadravathi. Marigowda, Chaitali Dey, Arindam Banerjee, Hanumant Kulkarni, Milind Sagar, Shiv Ram Krishn, et al. (2024). Supplementary Data from BCA101 is a Tumor-Targeted Bifunctional Fusion Antibody that Simultaneously Inhibits EGFR and TGF-β Signalling to Durably Suppress Tumor Growth .

Srinivas Reddy Boreddy, Reshmi Nair, Prashant Kumar Pandey, Anshu Kuriakose, Shivakumar Bhadravathi Marigowda, Chaitali Dey, Arindam Banerjee, Hanumant Kulkarni, Milind Sagar, Shiv Ram Krishn, et al. (2023). Data from BCA101 Is a Tumor-Targeted Bifunctional Fusion Antibody That Simultaneously Inhibits EGFR and TGFβ Signaling to Durably Suppress Tumor Growth .

Srinivas Reddy Boreddy, Reshmi Nair, Prashant Kumar Pandey, Anshu Kuriakose, Shivakumar Bhadravathi Marigowda, Chaitali Dey, Arindam Banerjee, Hanumant Kulkarni, Milind Sagar, Shiv Ram Krishn, et al. (2023). Data from BCA101 Is a Tumor-Targeted Bifunctional Fusion Antibody That Simultaneously Inhibits EGFR and TGFβ Signaling to Durably Suppress Tumor Growth .

Srinivas Reddy Boreddy, Reshmi Nair, Prashant Kumar Pandey, Anshu Kuriakose, Shivakumar Bhadravathi Marigowda, Chaitali Dey, Arindam Banerjee, Hanumant Kulkarni, Milind Sagar, Shiv Ram Krishn, et al. (2023). Supplementary Data from BCA101 Is a Tumor-Targeted Bifunctional Fusion Antibody That Simultaneously Inhibits EGFR and TGFβ Signaling to Durably Suppress Tumor Growth .

Srinivas Reddy Boreddy, Reshmi Nair, Prashant Kumar Pandey, Anshu Kuriakose, Shivakumar Bhadravathi Marigowda, Chaitali Dey, Arindam Banerjee, Hanumant Kulkarni, Milind Sagar, Shiv Ram Krishn, et al. (2023). Supplementary Data from BCA101 Is a Tumor-Targeted Bifunctional Fusion Antibody That Simultaneously Inhibits EGFR and TGFβ Signaling to Durably Suppress Tumor Growth .

Srinivas Reddy Boreddy, Reshmi Nair, Prashant Kumar Pandey, Anshu Kuriakose, Shivakumar Bhadravathi Marigowda, Chaitali Dey, Arindam Banerjee, Hanumant Kulkarni, Milind Sagar, Shiv Ram Krishn, et al. (2023). Data from BCA101 Is a Tumor-Targeted Bifunctional Fusion Antibody That Simultaneously Inhibits EGFR and TGFβ Signaling to Durably Suppress Tumor Growth .

Srinivas Reddy Boreddy, Reshmi Nair, Prashant Kumar Pandey, Anshu Kuriakose, Shivakumar Bhadravathi Marigowda, Chaitali Dey, Arindam Banerjee, Hanumant Kulkarni, Milind Sagar, Shiv Ram Krishn, et al. (2023). Supplementary Data from BCA101 Is a Tumor-Targeted Bifunctional Fusion Antibody That Simultaneously Inhibits EGFR and TGFβ Signaling to Durably Suppress Tumor Growth .

Srinivas Reddy Boreddy, Reshmi Nair, Prashant Kumar Pandey, Anshu Kuriakose, Shivakumar Bhadravathi Marigowda, Chaitali Dey, Arindam Banerjee, Hanumant Kulkarni, Milind Sagar, Shiv Ram Krishn, et al. (2023). Supplementary Data from BCA101 Is a Tumor-Targeted Bifunctional Fusion Antibody That Simultaneously Inhibits EGFR and TGFβ Signaling to Durably Suppress Tumor Growth .

CONFERENCE PAPER

1368 A novel bispecific BCA356 targeting tumour antigen CAIX conjugated to an attenuated IL12 demonstrates pre-clinical efficacy with potential for limited systemic toxicity @inproceedings{Nair_2022, title={1368 A novel bispecific BCA356 targeting tumour antigen CAIX conjugated to an attenuated IL12 demonstrates pre-clinical efficacy with potential for limited systemic toxicity}, url={http://dx.doi.org/10.1136/jitc-2022-sitc2022.1368}, DOI={10.1136/jitc-2022-sitc2022.1368}, booktitle={Regular and Young Investigator Award Abstracts}, publisher={BMJ Publishing Group Ltd}, author={Nair, Pradip and Goswamy, Arvind and Bhatnagar, Jaya and Boreddy, Srinivas and Nair, Reshmi and Krishn, Shiv and Kuriakose, Anshu and Pandey, Prashanth and Kulkarni, Hanumant and Punnath, Kishore and Sagar, Milind and V, Prashanthakumara and TK, Thulsi and Sinha, Abhishek and DR, Ravindra and Salazar, Rachel}, year={2022}, month=nov } . Regular and Young Investigator Award Abstracts.